Antidepressant and additional transcranial electrial cortex stimulatio

Not Applicable

• Conditions: F32; F33; Depressive episode; Recurrent depressive disorder

• Registration Number: DRKS00008009
• Lead Sponsor: Psychiatrische Klinik

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-04-13
• Study Completion: 2018-03-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting stopped after recruiting started
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

depressive syndrome, independent from diagnosis. HAMD>8. informed consent.

Exclusion Criteria

gravidity. other severe psychiatric disorder, substance abuse, acute suicidality. brain/skull trauma. Severe neurologic or somatic disease, epilepsy. metal implants in head/neck. Cancer. Intolerability or former loss of efficacy of citalopram/escitlopram.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary endpoint is with completion of 20th tDCS, 10 working days after begin of the study. First measurement (baseline) takes place before first stimulation at day 0 with assessment of HAMD. Second measurement (final measurement) takes place after completion of the 20th stimulation with the assessment of the percentual reduction of depression severtiy in the Hamilton Depression Rating Scale (HAMD)

Secondary Outcome Measures

Name	Time	Method
Feasability and tolerability of 20 stimulations with the Comfort Rating Questionnaire (CRQ) immediatey after completion of tDCS (20th stimulation, day 10).